# Cell Therapy Core

> **NIH NIH P01** · JOHNS HOPKINS UNIVERSITY · 2022 · $363,333

## Abstract

Cell Processing Core 
Project Summary 
The application of T cell-based immunotherapies to augment the anti-tumor and/or anti-viral immune responses 
following autologous or allogeneic blood or marrow transplantation (BMT) has dramatically increased over the 
past several years. The development and translation of these T cell-based immunotherapy products for clinical 
applications requires scientific and technical expertise, highly skilled manufacturing staff, and a facility that meets 
the regulatory requirements to perform the clinical manufacturing procedures. Therefore, the principle objective 
of the Cell Processing Core is to support the projects in this program project grant by providing the cell processing 
expertise and facilities for the manufacture of the T cell-based immunotherapy products that have been 
developed and validated by the scientific teams at The Johns Hopkins Medicine Sidney Kimmel Comprehensive 
Cancer Center Cell Therapy Laboratory (JHM-SKCCC-CTL) and Children National Health System’s Cell 
Enhancement and Technologies for Immunotherapy Cell Therapy Laboratory (CNHS-CETI-CTL). Both facilities 
operate under current Good Manufacturing Tissue/Manufacturing Practices (cGTP/cGMP) conditions, 
appropriate for the manufacture of clinical products administered to patients. Specifically, JHM-SKCCC-CTL will 
manufacture activated marrow infiltrating lymphocytes (aMILs) T cell therapy products for Project 2; the CNHS- 
CETI-CLT program will manufacture two separate T cell therapy products, 1) T cells targeting tumor-associated 
antigens (TAA-T), and 2) T cells targeting HIV (HXTC) antigens, for Project 3. Both cell processing teams and 
facilities have extensive and complementary expertise to successfully meet the T cell therapy product needs 
proposed in these program projects.

## Key facts

- **NIH application ID:** 10486001
- **Project number:** 5P01CA225618-04
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** VICTOR M LEMAS
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $363,333
- **Award type:** 5
- **Project period:** 2019-05-21 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10486001

## Citation

> US National Institutes of Health, RePORTER application 10486001, Cell Therapy Core (5P01CA225618-04). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10486001. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*